Trials / Terminated
TerminatedNCT00160147
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 65 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a 10-week study with bifeprunox and placebo in elderly subjects with psychosis and behavioral disturbances associated with dementia of the alzheimer's type.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bifeprunox | One week titration with dose adjustments |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2005-09-12
- Last updated
- 2015-02-09
Locations
51 sites across 5 countries: United States, Czechia, Estonia, Israel, Poland
Source: ClinicalTrials.gov record NCT00160147. Inclusion in this directory is not an endorsement.